聚乙二醇化赛妥珠单抗治疗类风湿性血管炎所致腿部溃疡。 - Suppr

Suppr

超能文献

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis.

作者信息

Meling Maureen Tania, Minagawa Akane, Miyake Tomomi, Ashida Atsuko, Okuyama Ryuhei

机构信息

Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.

出版信息

JAAD Case Rep. 2021 Oct 13;18:12-14. doi: 10.1016/j.jdcr.2021.10.004. eCollection 2021 Dec.

DOI:10.1016/j.jdcr.2021.10.004

PMID:34786446

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8577500/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/356c/8577500/85460bd7c447/gr1.jpg

相似文献

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis.

JAAD Case Rep. 2021 Oct 13;18:12-14. doi: 10.1016/j.jdcr.2021.10.004. eCollection 2021 Dec.

Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.

Rheumatol Int. 2017 Sep;37(9):1441-1452. doi: 10.1007/s00296-017-3736-z. Epub 2017 May 18.

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.

Mod Rheumatol. 2014 Sep;24(5):715-24. doi: 10.3109/14397595.2013.864224. Epub 2013 Dec 9.

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.

Int J Rheum Dis. 2020 Mar;23(3):316-324. doi: 10.1111/1756-185X.13780. Epub 2020 Jan 19.

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.

Ann Rheum Dis. 2017 Aug;76(8):1348-1356. doi: 10.1136/annrheumdis-2016-210246. Epub 2017 Feb 2.

Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.

J Clin Pharm Ther. 2020 Oct;45(5):1179-1182. doi: 10.1111/jcpt.13117. Epub 2020 Jan 28.

Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.

Mod Rheumatol. 2014 Jul;24(4):552-60. doi: 10.3109/14397595.2013.843764. Epub 2013 Nov 1.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD007649. doi: 10.1002/14651858.CD007649.pub4.

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoeconomics. 2017 Nov;35(11):1141-1151. doi: 10.1007/s40273-017-0521-5.

本文引用的文献

Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study.

EJNMMI Res. 2016 Dec;6(1):88. doi: 10.1186/s13550-016-0245-0. Epub 2016 Dec 12.

Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy.

Rheumatology (Oxford). 2014 Jan;53(1):145-52. doi: 10.1093/rheumatology/ket326. Epub 2013 Oct 8.

Rheumatoid vasculitis: vanishing menace or target for new treatments?

Curr Rheumatol Rep. 2010 Dec;12(6):414-9. doi: 10.1007/s11926-010-0130-1.

Certolizumab pegol.

MAbs. 2010 Mar-Apr;2(2):137-47. doi: 10.4161/mabs.2.2.11271.

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.

J Immunol Methods. 2009 Aug 31;348(1-2):36-41. doi: 10.1016/j.jim.2009.06.009. Epub 2009 Jun 28.

Vasculitis induced by tumor necrosis factor-targeted therapies.

Curr Rheumatol Rep. 2008 Dec;10(6):442-8. doi: 10.1007/s11926-008-0072-z.

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.

Inflamm Bowel Dis. 2007 Nov;13(11):1323-32. doi: 10.1002/ibd.20225.

Chronic venous insufficiency and venous leg ulceration.

J Am Acad Dermatol. 2001 Mar;44(3):401-21; quiz 422-4. doi: 10.1067/mjd.2001.111633.

The diagnostic value of perivascular infiltrates in muscle biopsy specimens for the assessment of rheumatoid vasculitis.

Ann Rheum Dis. 1998 Feb;57(2):114-7. doi: 10.1136/ard.57.2.114.

IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy.

Clin Exp Immunol. 1981 Jan;43(1):54-63.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis.

作者信息

Meling Maureen Tania, Minagawa Akane, Miyake Tomomi, Ashida Atsuko, Okuyama Ryuhei

机构信息

Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.

出版信息

JAAD Case Rep. 2021 Oct 13;18:12-14. doi: 10.1016/j.jdcr.2021.10.004. eCollection 2021 Dec.

DOI:10.1016/j.jdcr.2021.10.004

PMID:34786446

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8577500/

Abstract

摘要

相似文献

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis.

JAAD Case Rep. 2021 Oct 13;18:12-14. doi: 10.1016/j.jdcr.2021.10.004. eCollection 2021 Dec.

Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.

Rheumatol Int. 2017 Sep;37(9):1441-1452. doi: 10.1007/s00296-017-3736-z. Epub 2017 May 18.

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.

Mod Rheumatol. 2014 Sep;24(5):715-24. doi: 10.3109/14397595.2013.864224. Epub 2013 Dec 9.

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.

Int J Rheum Dis. 2020 Mar;23(3):316-324. doi: 10.1111/1756-185X.13780. Epub 2020 Jan 19.

Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

Ann Rheum Dis. 2017 Aug;76(8):1348-1356. doi: 10.1136/annrheumdis-2016-210246. Epub 2017 Feb 2.

Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.

J Clin Pharm Ther. 2020 Oct;45(5):1179-1182. doi: 10.1111/jcpt.13117. Epub 2020 Jan 28.

Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.

Mod Rheumatol. 2014 Jul;24(4):552-60. doi: 10.3109/14397595.2013.843764. Epub 2013 Nov 1.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD007649. doi: 10.1002/14651858.CD007649.pub4.

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoeconomics. 2017 Nov;35(11):1141-1151. doi: 10.1007/s40273-017-0521-5.

本文引用的文献

Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study.

EJNMMI Res. 2016 Dec;6(1):88. doi: 10.1186/s13550-016-0245-0. Epub 2016 Dec 12.

Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy.

Rheumatology (Oxford). 2014 Jan;53(1):145-52. doi: 10.1093/rheumatology/ket326. Epub 2013 Oct 8.

Rheumatoid vasculitis: vanishing menace or target for new treatments?

Curr Rheumatol Rep. 2010 Dec;12(6):414-9. doi: 10.1007/s11926-010-0130-1.

Certolizumab pegol.

MAbs. 2010 Mar-Apr;2(2):137-47. doi: 10.4161/mabs.2.2.11271.

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.

J Immunol Methods. 2009 Aug 31;348(1-2):36-41. doi: 10.1016/j.jim.2009.06.009. Epub 2009 Jun 28.

Vasculitis induced by tumor necrosis factor-targeted therapies.

Curr Rheumatol Rep. 2008 Dec;10(6):442-8. doi: 10.1007/s11926-008-0072-z.

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.

Inflamm Bowel Dis. 2007 Nov;13(11):1323-32. doi: 10.1002/ibd.20225.

Chronic venous insufficiency and venous leg ulceration.

J Am Acad Dermatol. 2001 Mar;44(3):401-21; quiz 422-4. doi: 10.1067/mjd.2001.111633.

The diagnostic value of perivascular infiltrates in muscle biopsy specimens for the assessment of rheumatoid vasculitis.

Ann Rheum Dis. 1998 Feb;57(2):114-7. doi: 10.1136/ard.57.2.114.

IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy.

Clin Exp Immunol. 1981 Jan;43(1):54-63.